- Home
- Programs and Groups
- Shared Resources
- Faculty
- Clinical Trials
- Tumor Registry
- Education
- About DCI
Quick Links
Breadcrumbs Navigation
Home > Clinical Trials > Adult Clinical Trials - Leukemia and multiple myelomaAdult Clinical Trials - Leukemia and multiple myeloma
If you need additional information about any of the trials listed or would like to inquire about other open trials, please contact Donna Adams, ANP at 919-668-4716 or Julie Warzecho, RN 919-681-4769 for leukemia trials. For information on Myeloma trials call Juliana Gardner, RN 919-668-6524.
Items 1 - 17 of 17
Items 1 - 17 of 17
A Multi-Center Phase I/II, Open-Label, Dose-Finding Pilot Study of the Combination of Carflizomib and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
Principal Investigator: Cristina Gasparetto
Phase: Phase I
Phone: 919-668-6524
Principal Investigator: Cristina Gasparetto
Phase: Phase I
Phone: 919-668-6524
A randomized, prospective, double blind, placebo-controlled, phase 3 study of US-ATG-F prophylaxis as a supplement to standard of care prophylaxis to prevent moderate to severe chronic GVHD in adult AML, ALL, and MDS patients after allogeneic stem cell transplantation from unrelated donors
Principal Investigator: Mitchell Horwitz
Phase: Phase III
Phone: 919-681-9710
Principal Investigator: Mitchell Horwitz
Phase: Phase III
Phone: 919-681-9710
AALL0433 Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Principal Investigator: Susan Kreissman
Phase: Phase III
Phone: 919-684-3401
Principal Investigator: Susan Kreissman
Phase: Phase III
Phone: 919-684-3401
AALL0434 Intensified Methotrexate, Nelarabine Compound 506U78; IND#52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma
Principal Investigator: Susan Kreissman
Phase: Phase III
Phone: 919-684-3401
Principal Investigator: Susan Kreissman
Phase: Phase III
Phone: 919-684-3401
Genetic Epidemiology of Chronic Lymphocytic Leukemia
Principal Investigator: Mark Lanasa
Phase: N/A
Phone: 919-416-8029
Principal Investigator: Mark Lanasa
Phase: N/A
Phone: 919-416-8029
A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 319 in Adult Subjects with Relapsed or Refractory Lymphoid Malignancies (Amgen Protocol Number: 20101262)
Principal Investigator: Mark Lanasa
Phase: Phase I
Phone: 919-668-1026
Principal Investigator: Mark Lanasa
Phase: Phase I
Phone: 919-668-1026
A Phase 1b Study Evaluating The Safety and Tolerability of ABT-199 in Combination with Rituximab in Subjects with Relapsed or Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (M13-365)
Principal Investigator: Mark Lanasa
Phase: Phase I
Phone: 919-668-1026
Principal Investigator: Mark Lanasa
Phase: Phase I
Phone: 919-668-1026
Lenalidomide in Combination with Plerixafor in Patients with Previously Treated Chronic Lymphocytic Leukemia
Principal Investigator: Mark Lanasa
Phase: Phase I
Phone: 919-668-1026
Principal Investigator: Mark Lanasa
Phase: Phase I
Phone: 919-668-1026
A phase III, open label, randomized, multicenter trial of ofatumumab maintenance treatment versus no further treatment in subjects with relapsed chronic lymphocytic leukemia (CLL) who have responded to induction therapy (OMB112517)
Principal Investigator: Mark Lanasa
Phase: Phase III
Phone: 919-668-1026
Principal Investigator: Mark Lanasa
Phase: Phase III
Phone: 919-668-1026
A PHASE I STUDY OF WT1 PEPTIDES TO INDUCE ANTI-LEUKEMIA IMMUNE RESPONSES FOLLOWING AUTOLOGOUS OR ALLOGENEIC TRANSPLANTATION FOR AML, CML, ALL, MDS, AND WT1 EXPRESSING B CELL MALIGNANCIES
Principal Investigator: Michael Morse
Phase: Phase I
Phone: 919-684-7115
Principal Investigator: Michael Morse
Phase: Phase I
Phone: 919-684-7115
A Phase 3, Multicenter, Randomized Study to Evaluate the Substitution of Marqibo® (Vincristine Sulfate Liposomes Injection, VSLI) for Standard Vincristine Sulfate Injection (VSI) in the Induction, Intensification, and Maintenance Phases of Combination Chemotherapy in the Treatment of Subjects = 60 Years Old with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
Principal Investigator: Arati Rao
Phase: Phase III
Phone: 919-681-4769
Principal Investigator: Arati Rao
Phase: Phase III
Phone: 919-681-4769
PHASE III, MULTICENTER, RANDOMIZED, TRIAL OF CPX-351 (CYTARABINE:DAUNORUBICIN) LIPOSOME INJECTION VERSUS CYTARABINE AND DAUNORUBICIN IN PATIENTS 60-75 YEARS OF AGE WITH UNTREATED HIGH RISK (SECONDARY) AML. (Protocol CLTR0310-301)
Principal Investigator: Arati Rao
Phase: Phase III
Phone: 919-681-4769
Principal Investigator: Arati Rao
Phase: Phase III
Phone: 919-681-4769
Studying Interventions for Managing Patients with Chronic Myeloid Leukemia in Chronic Phase: the 5-year Prospective Cohort Study (SIMPLICITY)
Principal Investigator: David Rizzieri
Phase: N/A
Phone: 919-668-4716
Principal Investigator: David Rizzieri
Phase: N/A
Phone: 919-668-4716
A Phase 1-2, Dose Escalation, Multicenter Study of Two Subcutaneous Regimens of SGI-110, a DNA Hypomethylating Agent, in Subjects with Intermediate or High-Risk Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
Principal Investigator: David Rizzieri
Phase: Phase I
Phone: 919-681-4769
Principal Investigator: David Rizzieri
Phase: Phase I
Phone: 919-681-4769
An open label, multicenter, phase II study to evaluate efficacy and safety of the BiTE antibody blinatumomab in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL) (Study Protocol MT103-211)
Principal Investigator: David Rizzieri
Phase: Phase II
Phone: 919-681-4769
Principal Investigator: David Rizzieri
Phase: Phase II
Phone: 919-681-4769
A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (CYC682 12)
Principal Investigator: David Rizzieri
Phase: Phase III
Phone: 919-681-4769
Principal Investigator: David Rizzieri
Phase: Phase III
Phone: 919-681-4769
Phase II study of subcutaneous VELCADE and oral cyclophosphamide-based induction followed by sequential maintenance therapy with VELCADE and Revlimid (lenalidomide) for newly diagnosed multiple myeloma in non-transplant candidates: An entirely non-intravenous regimen
Principal Investigator: Sascha Tuchman
Phase: Phase II
Phone: 919-668-6524
Principal Investigator: Sascha Tuchman
Phase: Phase II
Phone: 919-668-6524
